A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43905285" target="_blank" >RIV/00216208:11120/12:43905285 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064211:_____/12:#0000125
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >http://dx.doi.org/10.1007/s00280-011-1771-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >10.1007/s00280-011-1771-0</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Popis výsledku v původním jazyce
This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination. Methods: Patients (n = 26) with advanced-stage non-small-cell lung cancer received intravenous cisplatin 100 mg/m2 on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m2 weekly. Continuous oral bexarotene therapy (400 mg/m2/day) was initiated at day 4. Lipid-lowering therapy was initiated in all patients due to hypertriglyceridemia associated with bexarotene use. PK profiles of the chemotherapeutic agents were obtained on day 1 (without bexarotene) and during cycles 2-4 (with bexarotene). Vinorelbine (n = 18) and free cisplatin (n = 17) PK parameters in evaluable patients were determined using non-compartmental methods. Results: Mean vinorelbine and free cisplati
Název v anglickém jazyce
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Popis výsledku anglicky
This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination. Methods: Patients (n = 26) with advanced-stage non-small-cell lung cancer received intravenous cisplatin 100 mg/m2 on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m2 weekly. Continuous oral bexarotene therapy (400 mg/m2/day) was initiated at day 4. Lipid-lowering therapy was initiated in all patients due to hypertriglyceridemia associated with bexarotene use. PK profiles of the chemotherapeutic agents were obtained on day 1 (without bexarotene) and during cycles 2-4 (with bexarotene). Vinorelbine (n = 18) and free cisplatin (n = 17) PK parameters in evaluable patients were determined using non-compartmental methods. Results: Mean vinorelbine and free cisplati
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Cancer Chemotherapy and Pharmacology
ISSN
0344-5704
e-ISSN
—
Svazek periodika
69
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
815-824
Kód UT WoS článku
000302325600025
EID výsledku v databázi Scopus
—